Active, not recruitingPhase 2NCT02678182

Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial

Studying Infantile neuroaxonal dystrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Royal Marsden NHS Foundation Trust
Intervention
Capecitabine(drug)
Enrollment
494 target
Eligibility
18 years · All sexes
Timeline
20152027

Study locations (1)

Collaborators

MedImmune LLC · Clovis Oncology, Inc. · Eli Lilly and Company · AstraZeneca

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02678182 on ClinicalTrials.gov

Other trials for Infantile neuroaxonal dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Infantile neuroaxonal dystrophy

← Back to all trials